Thioglycosides Act as Metabolic Inhibitors of Bacterial Glycan Biosynthesis

Glycans that coat the surface of bacteria are compelling antibiotic targets because they contain distinct monosaccharides that are linked to pathogenesis and are absent in human cells. Disrupting glycan biosynthesis presents a path to inhibiting the ability of a bacterium to infect the host. We previously demonstrated that O-glycosides act as metabolic inhibitors and disrupt bacterial glycan biosynthesis. Inspired by a recent study which showed that thioglycosides (S-glycosides) are 10 times more effective than O-glycosides at inhibiting glycan biosynthesis in mammalian cells, we crafted a panel of S-glycosides based on rare bacterial monosaccharides. The novel thioglycosides altered glycan biosynthesis and fitness in pathogenic bacteria but had no notable effect on glycosylation or growth in beneficial bacteria or mammalian cells. In contrast to findings in mammalian cells, S-glycosides and O-glycosides exhibited comparable potency in bacteria. However, S-glycosides exhibited enhanced selectivity relative to O-glycosides. These novel metabolic inhibitors will allow selective perturbation of the bacterial glycocalyx for functional studies and set the stage to expand our antibiotic arsenal.

B acteria cover their cells with a carbohydrate-based coat of armor termed the glycocalyx.Proper construction of cell envelope glycans that comprise the glycocalyx, including peptidoglycan, lipopolysaccharide (LPS), capsular polysaccharide (CPS), and glycosylated proteins (Figure 1A), is critical for bacterial fitness and survival. 1Among their roles, glycans mediate host cell binding, 2 evade immune cells, 3 contribute to biofilm formation, 4,5 aid with protein folding, and provide structural rigidity. 6As a testament to their functional and clinical importance, bacterial glycans are the target of blockbuster antibiotics including penicillin 7 and vancomycin 8 and antibiotics of last resort such as polymyxin. 9Due to the emergence and spread of resistance to existing antibiotics, there is an urgent need to identify novel molecules that perturb bacterial glycan biosynthesis.
Bacterial glycans are compelling molecular targets due to their unique structures. 10,11While mammalian and bacterial cells are both coated with a glycocalyx, their structures are markedly different.Glycans on mammalian cells are composed of only 10 monosaccharides, whereas ≥700 monosaccharides constitute bacterial glycans. 12These monosaccharides include rare deoxy amino sugars that are expressed by a subset of medically significant bacterial pathogens.For example, di-Nacetyl D-bacillosamine (D-Bac), 13 D-2,4-diacetamido-2,4,6trideoxy galactose (D-DATDG), and N-acetyl D-fucosamine (D-FucNAc) 14,15 are a sampling of exclusively bacterial sugars incorporated into higher-order glycans on the priority pathogens Helicobacter pylori, 16,17 Campylobacter jejuni, 18 and Pseudomonas aeruginosa 19 (Figure 1B).Due to the presence of these monosaccharides on selected pathogens and their absence in mammalian cells, these structures are potential targets of selective interference. 20enetic perturbation of glycan biosynthesis attenuates bacterial virulence.For example, C. jejuni protein glycosylation mutants led to reduced adherence and invasion of host cells. 21n P. aeruginosa, pilin glycosylation is a virulence factor that led to establishment and maintenance of infection in the lung. 22In H. pylori, insertional inactivation of the general protein glycosylation system led to less motility, diminished biofilm formation, and reduced adhesion to host cells relative to H. pylori with intact protein glycosylation. 23The essential role of bacterial glycans in pathogenesis underscores the need for small-molecule perturbation strategies.
There have been some recent successes with the development of small-molecule inhibitors of bacterial glycosylation enzymes.In 2014, Logan and co-workers performed a highthroughput screen to identify inhibitors of pseudaminic acid biosynthesis, a monosaccharide critical for flagellin glycosylation in C. jejuni and H. pylori. 24In 2017, De Schutter and colleagues used a fragment-based and high-throughput screening strategy to identify a potent small-molecule inhibitor of PglD, a UDP-amino-sugar acetyltransferase involved in D-Bac biosynthesis. 25In 2017, Xu and colleagues screened nonsubstrate-like molecules to identify a covalent inhibitor of LgtC, an α-1,4-galactosyltransferase involved in bacterial lipooligosaccharide biosynthesis. 26These inhibitors of glycosylation enzymes are potent at low concentrations but must overcome the obstacle of passing through the bacterial cell envelope to gain access to their enzyme targets.Moreover, in vitro screening requires knowledge of and access to glycan processing enzymes and their substrates, as well as robust assays; challenges accessing this information and these materials can stymie the process.
Cell-based assays offer an attractive alternative to screening glycosylation enzymes in vitro, as they embed cell entry as a criterion to identify "hits" and circumvent the need for full pathway characterization to screen inhibitors.In 2018, Zhang et al. used a cell-based screen to identify LPS biosynthesis and transport inhibitors, ultimately revealing an LPS biogenesis inhibitor. 27In Williams et al., we reported a metabolic oligosaccharide engineering (MOE) 11,28 cell-based screen to identify inhibitors of bacterial glycan biosynthesis (Figure 1C). 29In this approach, we employed an azide-containing monosaccharide analogue that is processed by permissive glycan biosynthesis pathways to serve as a reporter for glycan biosynthesis in bacteria.Then, azide-selective bioorthogonal chemistries, including Staudinger ligation with phosphine probes and click chemistry with cyclooctyne probes, 30 were used to detect intact versus disrupted glycan biosynthesis in cells treated with putative glycosylation inhibitors.This screening method, coupled to the synthesis of substrate analogues based on rare bacterial monosaccharide scaffolds, led to the discovery of O-glycoside metabolic inhibitors that disrupt bacterial glycan biosynthesis and recapitulate fitness defects observed by genetic disruption. 29he previously reported metabolic inhibitors 1−3 are Oglycosides that act as decoy substrates (Figure 2B). 29Briefly, substrate decoys compete with endogenous acceptor substrates for glycosyltransferase-mediated addition of monosaccharides. 31Treatment of cells with a substrate decoy leads to the buildup of glycans on substrate decoys rather than on  endogenous substrates, causing concomitant truncation of newly synthesized glycans on the bacterial cell surface (Figure 2A).−35 Recently, Matta, Neelamegham, and co-workers reported that thioglycosides (S-glycosides) are 10x more effective than O-glycosides at inhibiting glycan biosynthesis in mammalian cells. 32This enhanced inhibition is due in part to the resistance of Sglycosides to hydrolysis by glycosidases within mammalian cells. 32Motivated by this successful precedent, we sought to develop S-glycosides based on rare bacterial monosaccharide substrates and assess their efficacy as metabolic inhibitors of bacterial glycan biosynthesis.
Herein, we report the synthesis of novel S-glycoside analogues of the rare deoxy amino bacterial sugars D-Bac, D-DATDG, and D-FucNAc (Figure 2C; compounds 4−6) and their evaluation as metabolic glycan inhibitors in pathogenic and symbiotic bacteria, as well as human host cells.As described below, the novel thioglycosides metabolically inhibit bacterial glycoprotein biosynthesis in H. pylori and precipitate a range of functional defects.By contrast, these analogues led to no detectable changes in glycan biosynthesis in the symbiotic intestinal bacteria Bacteroides fragilis and a human gastric adenocarcinoma cell line, both of which lack these rare monosaccharide scaffolds.In contrast to differences in potency in mammalian cells, S-glycosides and O-glycosides exhibited comparable potency in bacteria.However, S-glycosides exhibited enhanced selectivity relative to O-glycosides.These novel metabolic inhibitors set the stage for further probing and characterizing the functional consequence of perturbing glycans with selectivity.This work opens the door to unraveling structure−function relationships of bacterial glycans in the context of complex microbial communities, refining monosaccharide-based interference agents, and developing new glycosylation-based strategies to eradicate pathogenic infections.
■ RESULTS AND DISCUSSION Design and Synthesis of Thioglycosides.Inspired by the recent demonstration that thioglycosides are efficient substrate decoys that inhibit glycan biosynthesis in mammalian cells, we hypothesized that S-glycosides based on rare bacterial monosaccharide substrates would be effective metabolic inhibitors of bacterial glycan biosynthesis.We focused on derivatives of the rare bacterial monosaccharides D-Bac, D-DATDG, and D-FucNAc due to expedient syntheses of these scaffolds, 36,37 their known utilization by select bacterial pathogens, 17 and successes with O-glycosides based on these monosaccharides. 29As a first design element based on successful precedents with O-benzyl-glycosides to inhibit bacterial glycan biosynthesis (Figure 2B, 1−3), 17,28 we reasoned that S-benzyl-glycosides would likely be recognized by the requisite glycosyltransferases as decoy substrates.As a second design element, we chose to employ peracetylated analogues, as we and others have demonstrated that transient masking of hydrophilic hydroxyl groups on monosaccharide analogues with hydrophobic acetyl groups facilitates uptake and metabolic labeling in some bacteria. 17,28,38,39These design features are parallel to those adopted by Wang et al., who crafted the N-acetylglucosamine analogue-peracetylated Nacetylglucosamine-S-benzyl glycoside for their studies. 32Thus, we designed S-glycoside analogues BacSBn, DATSBn, and FucNSBn (Figure 2C, 4−6) that embody these two design criteria.
We synthesized the desired analogues 4−6 by adaptation of our previous approaches.In particular, the Kulkarni lab has established an efficient protocol for regioselective displacement of pyranosidic C-2, C-4 bistriflates with desired nucleophiles (azides or nitrites) giving access to a panel of functionalized rare sugar analogues including thioglycosides of bacillosamine, DAT, and fucosamine. 36,37Accordingly, the C-2 triflate is preferentially displaced using bulky TBAN 3 at lower temperature (−30 °C) owing to stereo-and electronic effects, which leaves the C-4 triflate to be displaced by NO 2 − to give an axially oriented C-4 hydroxyl.Here, we have exploited the protocol to install the thiobenzyl (SBn) handle on the known thioglycosides 8, 10, and 12. 29,36 Scheme 1 outlines the To begin with the synthesis of DATSBn, we first tried a direct coupling of DAT-thioglycoside 10 with commercially available benzylmercaptan using NIS and TfOH promotion conditions.However, the SBn-coupled compound was not obtained, and the starting thioglycoside 10 was recovered as such.A similar observation was noted while proceeding via glycosyl bromide.Therefore, the thioglycoside was converted to a hemiacetal using NBS, THF/H 2 O (4:1) conditions and subsequently to a trichloroimidate using CCl 3 CN, K 2 CO 3 in CH 2 Cl 2 .The obtained imidate donor on glycosylation with PhCH 2 SH in the presence of a TfOH promoter at 0 °C delivered the DATSBn-coupled compound 11 (α:β = 10:1) in 76% yield over three steps.The desired SBn-coupled product was confirmed by the presence of an AB quartet at δ 3.72 ppm in the 1 H NMR spectrum and an inverted peak at δ 34.1 ppm in the 13 C DEPT-135 NMR for CH 2 of the thiobenzyl group.Finally, the C-2, C-4 diazide was converted to NHAc by sequential conversion to amines using Zn, AcOH, followed by peracetylation with Ac 2 O to give target DATSBn analogue 5 in 81% yield over two steps.Similar reaction conditions for glycosylation of glycosyl imidate donors from bacillosamine thioglycoside 8 and fucosamine thioglycoside 12 furnished thiobenzyl analogues of the respective sugars 9 (61% yield, α:β = 20:1) and 13 (70% yield, α:β = 10:1).Zinc mediated reduction and peracetylation of the azide to acetamido furnished the protected desired SBn analogues, BacSBn 4 and FucSBn 6, in 75 and 77% yield, respectively, predominantly as α-anomers with a trace amount of the corresponding β-anomers.
Thioglycosides Inhibit Glycoprotein Biosynthesis in H. pylori.To ascertain whether the newly developed Sglycoside analogues of rare bacterial D-sugars (Figure 2C, 4− 6) are effective metabolic glycan inhibitors, we evaluated their impact on glycoprotein biosynthesis in H. pylori using an established MOE-based assay. 29Briefly, this cell-based assay hinges upon the metabolic incorporation of the azide- containing sugar-peracetylated N-azidoacetylglucosamine (Ac 4 GlcNAz) into a suite of glycoproteins synthesized by H. pylori's general glycosylation system. 38,40Here, we assessed the ability of each of the thioglycoside analogues to inhibit azidelabeled glycoprotein biosynthesis in H. pylori.Following our previously reported methods, metabolic labeling experiments were performed with Ac 4 GlcNAz as a positive control, with the azide-free sugar-peracetylated N-acetylglucosamine (Ac 4 GlcNAc) as a negative control or with Ac 4 GlcNAz in the presence of increasing concentrations (1−2 mM) of putative inhibitors 4−6 as experimental samples.After metabolic labeling for 4 days, proteins were harvested from lysed cells and reacted with a phosphine probe containing a FLAG peptide (Phos-FLAG) via Staudinger ligation to detect azide-labeled glycoproteins. 41,42Consistent with previous reports, Western blot analysis with anti-FLAG antibody revealed that H. pylori treated with Ac 4 GlcNAz synthesized the full complement of azide-labeled glycoproteins, whereas treatment with Ac 4 GlcNAc led to no detectable azidedependent signal (Figure 3A). 29,38,40These samples represent the highest and lowest amounts of signal, respectively, that we could expect to see in any given sample.Experimental samples treated with BacSBn 4 and FucSBn 6 elicited a concentrationdependent diminishment in the azide-dependent glycoprotein profile, with subtle effects at 1 mM and substantial diminishment at 2 mM treatments (Figure 3A, left).By contrast, DATSBn 5 appeared to abrogate the azide-dependent signal at both concentrations tested (Figure 3A, left).Coomassie staining of electrophoresed samples confirmed that all samples contain protein (Figure S1A), indicating that abrogation in the azide-dependent signal was not due to large differences in protein loading.Altogether, these data indicate that the three novel S-glycosides inhibit glycoprotein biosynthesis in H. pylori.
We next turned to carbohydrate-binding lectins as a complementary means to assess the effect of thioglycosides on H. pylori surface glycans.In particular, we assessed the binding of the lectin Concanavalin A (ConA) to untreated H. pylori versus H. pylori treated with 2 mM thioglycosides 4−6.Flow cytometry analysis revealed that ConA bound to untreated H. pylori at modest levels, and ConA binding was diminished by pretreatment of ConA with high concentrations of its monosaccharide ligand mannose (Figure 3A, right).Relative to untreated H. pylori, cells that were treated with BacSBn 4, DATSBn 5, and FucSBn 6 exhibited an increase in ConA binding (Figure 3A, right; Figure S1B), consistent with altered cell envelope glycan architecture.This result is in line with previous reports of small molecules or genetic disruption of glycoprotein biosynthesis causing increased lectin binding. 23,29nce we established that thiobenzyl glycosides disrupt glycan biosynthesis in H. pylori, we explored the effect of these compounds on fitness attributes.In particular, we scored fitness attributes that are critical for H. pylori to colonize and infect the host.Briefly, H. pylori was treated with S-glycosides at their lowest effective concentration (2 mM BacSBn 4 and FucSBn 6, 1 mM DATSBn 5) or left untreated; then relative strain fitness was scored.Monitoring growth by optical density at 600 nm (OD 600 ) revealed that untreated cells reached a stationary phase after 2 days, while cells treated with DATSBn 5 and BacSBn 4 had lagging growth relative to wild type but ultimately reached the stationary phase (Figure 3B).By contrast, cells treated with FucSBn 6 maintained a low OD 600 over the course of 8 days, suggesting that this compound significantly diminished H. pylori growth relative to untreated samples.Viability was measured by BacLight live−dead assay and indicated that all three S-glycosides reduced viability relative to untreated H. pylori, with BacSBn 4 and FucSBn 6 causing the most pronounced cell death (Figures 3B and S1C).Similarly, 4−6 significantly reduced motility on soft agar plates 43 relative to untreated cells (Figures 3B and S1C).Finally, untreated H. pylori produced a prominent biofilm that was detected by crystal violet staining; 44 of the treated samples, only treatment of FucSBn 6 led to a substantial perturbation of biofilm formation (Figures 3B and S1C).Holistically, these data indicate that FucSBn 6 causes the most dramatic fitness effects.
Taken together, the results of these studies indicate that the novel thioglycosides act as metabolic inhibitors that impair glycoprotein biosynthesis in H. pylori and precipitate a range of functional defects.These results support the importance of H. pylori's general protein glycosylation system in a variety of fitness attributes and offer important probes for understanding how glycan structure impacts function.The slightly different magnitudes of effects observed with 4, 5, and 6 may be due to where in the pathway these molecules intercept, possibly leading to relatively more or less elaborated glycans on cells as a result.Structural studies of glycans from treated versus untreated cells will shed light on the nuanced ways in which these S-glycosides inhibit glycan structures, thus opening the door to incisive structure−function relationships.
S-Glycosides Do Not Disrupt Commensal Bacteria or Human Cells.Once we established that S-glycosides 4−6 impede glycan biosynthesis in the pathogen H. pylori, we next explored the effect of these metabolic inhibitors on commensal gut bacteria.We focused on Bacteroides fragilis, as these bacteria are major constituents of the human gut that play critical roles in protection from pathogens and polysaccharide metabolism.Following Kasper and co-workers' metabolic labeling method to incorporate azides into B. fragilis capsular polysaccharide A, 39 bacteria were treated with peracetylated Nazidoacetylgalactosamine (Ac 4 GalNAz) and the effect of Sglycosides 4−6 on subsequent CPS biosynthesis was monitored.Consistent with literature reports, 39 surface glycans were robustly azide-labeled upon supplementation of B. fragilis with Ac 4 GalNAz (Figure 4A).Treatment of B. fragilis with Sglycosides had no apparent diminishment of capsular polysaccharide A biosynthesis, as evidenced by the sustained robust azide-dependent signal observed in all treatments (Figures 4A and S2A).If anything, the treatment of B. fragilis with FucSBn 6 led to a subtle increase in CPS biosynthesis.B. fragilis supplemented with S-glycosides 4−6 grew robustly relative to an untreated control (Figure 4B).These data indicate that these S-glycosides have a negligible effect on B. fragilis glycan biosynthesis and growth.In contrast, our previous work found that the O-glycoside BnFucNAc 3 interfered with CPS biosynthesis in B. fragilis. 29These results suggest that S-glycosides based on rare bacterial monosaccharides exhibited an enhanced selectivity relative to that of O-glycosides, thus setting the stage for glycan-based interference of pathogenic bacteria in a selective manner.
Curious about the effect of S-glycosides based on rare bacterial sugars on host cells, we set out to evaluate the effect of these analogues in the well-studied human gastric adenocarcinoma (AGS) cell line, a cell line that is an established model for epithelial cells that line the gastrointestinal tract. 45Treatment of AGS cells with the positive control sugar Ac 4 GalNAz led to an array of azide-labeled glycans in lysates and on cells (Figures 4C and S2B), consistent with incorporation of this substrate into cell surface mucin-type O-linked glycoproteins. 46Similar to treatment with the positive control sugar alone, treatment of AGS cells with Ac 4 GalNAz and S-glycosides 4−6 led to a robust azide-labeled glycan fingerprint (Figure 4C).These results suggest that the S-glycosides tested in this study have a minimal effect on the biosynthesis of the O-linked glycoprotein in AGS cells.Scoring AGS fitness of untreated cells versus cells treated with Sglycosides 4−6 indicated robust cell density and viability across all samples (Figure 4D,E).These findings suggest relative selectivity for thioglycoside-based metabolic decoys based on rare bacterial sugars, which is consistent with expectations based on monosaccharide utilization across different cell types.To the best of our knowledge, this is the first evidence that metabolic decoys based on bacterial glycans leave host glycans intact.

■ DISCUSSION
Given the importance of glycan biosynthesis in bacterial fitness, survival, and pathogenesis, expanding the repertoire of tools to disrupt these structures is critical.In particular, smallmolecule inhibitors of glycan biosynthesis offer a means to query structure−function relationships and indicate potential avenues for novel glycan-based interference strategies.Due to the profound structural complexity and diversity of bacterial glycans, coupled to a frequent lack of in-depth structural information about glycan biosynthesis pathways and enzymes, we turned to a substrate-based approach to design novel inhibitors.We built upon successful precedents from Esko, 33−35 Kim, 47 Matta, Neelamegham, 32 and others who used substrate decoys to divert glycan biosynthesis in mammalian cells, as well as our own work with peracetylated benzyl glycoside analogues of rare bacterial monosaccharides to metabolically inhibit bacterial glycan biosynthesis. 29Here, inspired by the 10-fold enhanced efficacy of thiobenzyl glycosides compared to benzyl glycosides in mammalian cells reported by Wang et al., 32 we produced a series of thiobenzyl glycoside analogues of rare bacterial monosaccharides to augment the existing toolkit.
Our data indicate that the novel S-glycosides act as metabolic glycan inhibitors in H. pylori, yet they have no appreciable effect on glycan biosynthesis in B. fragilis or human cells.In particular, FucSBn 6 impeded glycoprotein biosynthesis and precipitated defects in growth, motility, and biofilm formation assays in H. pylori (Figure 3) yet left B. fragilis and mammalian cell glycan biosynthesis and growth intact (Figure 4).These observed species-selective effects are likely due to differences in utilization of the rare bacterial monosaccharides Bac, DAT, and FucNAc by these cell types.Indeed, H. pylori is known to metabolically incorporate azide-containing analogues of these three monosaccharides, while neither B. fragilis nor mammalian cells incorporate Bac, DAT, and FucNAc probes into their cellular glycans. 17Selectivity is a desirable feature for teasing out the role of bacterial glycans in more complex environments, including within gut microbial communities and animal infection models. 11Thus, the novel S-glycoside inhibitors set the stage for selective glycan perturbation studies.
Different effects were observed among the three thioglycosides.Specifically, the choice of monosaccharide scaffolds appeared to influence the extent and pattern of inhibition and fitness defects in H. pylori (Figure 3).FucSBn 6 was the only inhibitor that elicited profound fitness defects across all three fitness assays in H. pylori (Figure 3B).Metabolic inhibitors based on different monosaccharide scaffolds may elicit different effects by inhibiting glycan biosynthesis at discrete points during construction of the higher-order glycan by glycosyltransferases.The profound inhibition and fitness defects caused by FucSBn 6 suggest that FucNAc may be a lynchpin within the elaborated glycan structure without which cells fare poorly.Access to structural information about how each of the thioglycosides impacts glycan biosynthesis will be critical to fully understand the compound-specific differences observed.
The experiments conducted in this project do not shed light on the mechanism of the inhibition of these compounds.While it is established in mammalian systems that inhibitors of this design act as substrate decoys that divert glycan biosynthesis onto mock substrates, their precise mode of action has not been established in bacterial systems.Molecular-level evidence of the buildup of glycans on thioglycosides 4−6 within cells would confirm this proposed mechanism.−50 These approaches could be translated to the study of elaborated glycans on decoy scaffolds in bacteria.If this proposed mechanism is correct, novel thioglycosides could analogously serve as readouts of bacterial glycan biosynthesis, ultimately enabling glycomic analyses that yield structural information.
The original impetus for this study was to compare the efficacy of bacterial S-glycosides 4−6 to that of previously tested bacterial O-glycosides 1−3.In contrast to the 10-fold difference in efficacy observed with S-versus O-glycosides based on GlcNAc in mammalian cells, 32 S-and O-glycosides based on rare bacterial monosaccharides exhibited comparable potency in bacteria, with mM concentrations required for efficacy. 29Wang et al. posited that S-glycosides are more potent in mammalian cells due to their resistance to hydrolysis by mammalian hexosaminidases, leading to enhanced stability and subsequent inhibitory activity. 32Our data indicate Wang et al.'s proposed mechanism of O-glycoside hydrolysis and relative S-glycoside stability is not as relevant in bacterial cells as it is in mammalian systems.Hexosaminidase activity might be more abundant in mammalian cells than in bacterial cells.Alternatively, bacterial hexosaminidases may cleave thioglycosides relatively efficiently, consistent with recent findings by Withers and co-workers. 51Moreover, there may be other cellular factors at play in bacterial cells, such as efficiency of compound uptake across the bacterial cell envelope, 52 that have a larger impact on overall efficacy of inhibitor than their relative resistance to hydrolysis.These findings raise questions about levels of glycosyl hydrolase activity in bacteria and their mechanisms of action, 53 as well as mechanisms of sugar uptake across the cell envelope.Chemical tools that address these remaining unknowns will further refine our understanding of the parameters dictating bacterial glycan biosynthesis, stability, and metabolism.
Given the absence of Bac, DAT, and FucNAc from human cells and their variable expression across bacteria, these structures have the potential to form the basis of new glycosylation-based strategies to eradicate pathogenic infec-tions.Selective perturbation of bacterial glycans offers a means to hypersensitize bacteria to existing antibiotics 54,55 and tailor the bacterial glycocalyx for the modulation of the host immune response. 11,56,57One limitation of this suite of compounds is the millimolar concentration required for inhibition, which puts these agents outside of a therapeutic efficacy window.As demonstrated by Wang et al., the identity of the aglycone in substrate decoys influences their relative activity. 32Thus, the potential exists to develop substrate-based metabolic inhibitors of bacterial monosaccharides bearing different aglycones as a means to enhance potency.Overall, S-glycosides are promising novel compounds that act with specificity and selectivity to modulate bacterial glycosylation and fitness.

■ CONCLUSIONS
Bacterial glycans are antibiotic targets and vaccine candidates with enormous untapped potential.This work describes novel metabolic inhibitors that disrupt bacterial glycan biosynthesis and fitness in pathogenic bacteria.The narrow effects of Sglycosides based on rare amino deoxy sugars are consistent with the apparent rare distribution of these epitopes and set the stage to further probe and perturb these structures.Broadly, this work expands the toolkit to interfere with bacterial glycans and gain critical insight into structure− function relationships.
■ METHODS Materials and Chemical Synthesis.Organic chemicals and anti-FLAG antibodies were purchased from Sigma-Aldrich.H. pylori strain G27 58 was a gift of Manuel Amieva (Stanford University).B. fragilis (ATCC 23745) and AGS cells (ATCC CRL-1739) were purchased from ATCC and grown according to the supplier's instructions.Ac 4 GlcNAc, Ac 4 GlcNAz, Ac 4 GalNAz, and Phos-FLAG were synthesized as previously described. 17,59,60BacSBn 4, DATSBn 5, and FucSBn 6 were synthesized by using standard organic chemistry procedures and characterized by standard techniques including 1 H and 13 C NMR spectroscopy and mass spectrometry.Analogues 4−6 were purified using flash silica gel chromatography.
Western Blot.Following metabolic labeling, cells were lysed and resultant protein lysates were standardized (BioRad's DC protein concentration assay) to a protein concentration of ∼2.5 mg mL −1 prior to reaction with 250 μM Phos-FLAG 42 overnight at room temperature.Reacted lysates were loaded onto a 12% Tris−HCl SDS-PAGE gel, separated by electro-phoresis, and transferred to nitrocellulose paper.Anti-FLAG-HRP was employed to visualize FLAG-tagged proteins via chemiluminescence.
Lectin Binding.H. pylori were treated with 2 mM BacSBn 4, DATSBn 5, or FucSBn 6 or left untreated for 3 days and then were probed with Alexa Fluor 488-conjugated Concanavalin A (ConA).As a negative control, ConA was preincubated with 400 mM mannose (carbo-block) prior to binding to untreated H. pylori.Cells were analyzed by flow cytometry on a BD Accuri C6 + (BD Biosciences) instrument, with 10,000 live cells gated for each replicate experiment.Data were analyzed by using FlowJo software (Ashland, OR).
Growth Curves.Bacterial growth was monitored during log phase and until bacteria reached stationary phase�over the course of 8 days for H. pylori and over 2 days for B. fragilis.Cells were inoculated into rich liquid media at a starting OD 600 of ∼0.1 and cultured in the absence of S-glycoside or the presence of 2 mM BacSBn 4, 1 mM DATSBn 5, or 2 mM FucSBn 6 at 37 °C with gentle shaking under microaerophilic or anaerobic conditions for H. pylori and B. fragilis, respectively.The OD 600 was measured at the indicated time points by using a SPECTROStar Nano 96-well plate reader (Thermo Fisher Scientific).
H. pylori Viability Measurements.H. pylori was standardized to an OD 600 of 0.4 in rich media and incubated for 4 days in the absence of S-glycoside or presence of 2 mM BacSBn 4, 1 mM DATSBn 5, or 2 mM FucSBn 6.Cells were analyzed prior to incubation and after 4 days of incubation using the LIVE/DEAD BacLight Bacterial Viability and Counting Kit (Invitrogen) according to manufacturer's instructions.Following staining with propidium iodide and SYTO 9 dyes included in the kit, cells were analyzed by flow cytometry using a BD Accuri C6 + (BD Biosciences, San Jose, California) instrument, with 10,000 live cells gated for each replicate.The number of live and dead H. pylori cells were counted using FlowJo software to determine the percentage of live H. pylori (% live = 100*[(# live cells)/(# live cells + # dead cells)]).
Motility Assays.H. pylori were treated with S-glycosides or left untreated, and then their ability to swarm was monitored over the course of 13 days.H. pylori cultures were standardized to an OD 600 between 0.3 and 0.4 in rich media and then incubated with no S-glycoside or with 2 mM BacSBn 4, 1 mM DATSBn 5, or 2 mM FucSBn 6 under microaerophilic conditions.Cells from each culture were concentrated by centrifugation and resuspended in rich media, and then 10 μL concentrated culture was plated onto soft agar plates supplemented with 4% agar and 10% fetal bovine serum.
Plates were incubated at 37 °C and 14% CO 2 , and the colony diameter was measured for 13 days and imaged on day 13.
Biofilm Formation Assays.The ability of H. pylori to form a biofilm in the absence or presence of thioglycosides was assessed following O'Toole's literature protocol. 44Bacteria were standardized to an OD 600 of 0.3 to 0.4 in rich liquid media in the absence of S-glycoside or with 2 mM BacSBn 4, 1 mM DATSBn 5, or 2 mM FucSBn 6, and samples were added in triplicate to the side wells of a 96-well plate.The bacteria were incubated for 5 days at 37 °C and 14% CO 2 .After incubation, the medium was carefully removed, and the biofilm was stained with 0.15% crystal violet.Side-view images of the triplicate wells were taken after staining to visualize biofilm production.The stained wells were then solubilized in 30% acetic acid in water, and the absorbance of the solution was quantified at 550 nm using a SPECTROstar Nano plate reader (Thermo Fisher Scientific).
AGS Cell Count and Viability.AGS cells were seeded at a density of 1 × 10 5 cells/mL in 1 mL of Ham's F12 Glutamax medium and cultured for 3 days in the absence or presence of 10 μM S-glycosides in a 48-well tissue culture plate.After 3 days, the media were aspirated, and 0.25% Trypsin and EDTA was added to each well for 5 min at 37 °C.This reaction was stopped by the addition of AGS media.To assess cell viability in the absence or presence of an inhibitor, Gibco Trypan blue stain (0.4%) was added to the cell suspension at a 1:1 ratio, and the cells were counted using a hemocytometer (Countess 3 Invitrogen).This analysis yielded the number of cells/mL and the % live cells.

Figure 1 .
Figure 1.Sampling of exclusively bacterial (A) glycans, (B) monosaccharides synthesized by Gram-negative pathogens, and (C) an MOE-based method to report on bacterial glycan biosynthesis.

Figure 2 .
Figure 2. Metabolic inhibitors disrupt glycan biosynthesis.(A) Schematic of benzyl glycosides acting as metabolic inhibitors to divert glycan biosynthesis onto decoy substrates, ultimately leading to truncated glycans on bacteria.(B) Precedented O-glycoside inhibitors from previous work.(C) Novel S-glycoside analogues of bacterial sugar scaffolds used as putative metabolic inhibitors in this study.

Figure 3 .
Figure 3. Novel S-glycosides inhibit glycan biosynthesis and decrease fitness in Helicobacter pylori.(A) Western blot analysis (left) reveals diminished glycoprotein biosynthesis in H. pylori upon treatment with BacSBn 4, DATBn 5, and FucSBn 6.The short side of the triangle represents the 1 mM S-glycoside treatment, and the tall part represents the 2 mM S-glycoside treatment.Flow cytometry analysis (right) reveals increased binding of ConA lectin in H. pylori treated with S-glycosides, consistent with perturbed cell surface glycan architecture.By contrast, pretreatment of ConA with 400 mM mannose (carbo-block) prior to probing untreated H. pylori led to decreased binding.(B) Measurement of growth, viability, motility, and biofilm demonstrates a range of fitness defects in H. pylori treated with S-glycosides, with FucSBn leading to the most marked effects relative to untreated (−) controls.The data shown are representative of replicate experiments (n = 3).

Figure 4 .
Figure 4. Glycan biosynthesis and growth remain intact in B. fragilis and mammalian cells following treatment with S-glycosides.(A) Western blot analysis shows intact biosynthesis of polysaccharide A in B. fragilis treated with 0.1−2 mM thioglycosides BacSBn 4, DATSBn 5, and FucSBn 6 that is comparable to levels in samples treated only with Ac 4 GalNAz.The increasing size of the shaded triangle corresponds to increasing concentrations of S-glycosides, with the short side of the triangle corresponding to 0.1 mM and the tallest part representing 2 mM.(B) B. fragilis exhibited robust growth across all treatments.(C) Western blot analysis of Ac 4 GalNAz-labeled O-linked glycoproteins in AGS samples indicates that treatment with 10 μM thioglycosides BacSBn 4, DATSBn 5, and FucSBn 6 has no apparent effect on glycoprotein biosynthesis.Density (D) and viability (E) of AGS cells are not significantly impacted by thioglycoside treatment relative to untreated controls (−).These data are representative of replicate experiments (n ≥ 2).

■ ASSOCIATED CONTENT * sı Supporting Information The
Supporting Information is available free of charge on the ACS Publications Web site.The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acsinfecdis.3c00324.Full experimental details, compound characterization data, and protein loading controls, mean fluorescence intensities of samples from flow cytometry analyses, and quantification of motility and biofilm (Figures S1 and S2) (PDF)